$27.75
-2.1%Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.
Weak cash conversion. Significant portion of earnings not converting to cashโreview working capital trends and capital intensity.
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโmonitor closely.
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
CTEV โข NYSE
| Claritev Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-284.3M | -1.6B | -91.7M | -572.9M | 102.1M | -520.6M | 9.7M | 36.2M | |
445.4M | 436.4M | 425.8M | 415.7M | 424.3M | 403.7M | 399.5M | 386.3M | |
-128.5M | -198M | -114.1M | -114.4M | 0.0 | -45M | -111.4M | -112.5M | |
27.8M | 26.6M | 18M | 16.7M | 18M | 406.1M | -14.9M | 4.7M | |
85.7M | 1.5B | -44.4M | 571.9M | -93M | 103.2M | -4.9M | 15.1M | |
(0.0) | (80.1M) | (0.0) | (0.0) | (0.0) | (3.9M) | (114.6M) | (116.6M) | |
-28.9M | -13.7M | -21.9M | 55.3M | -46.7M | 30M | 6.4M | -37.6M | |
117.3M | 107.6M | 171.7M | 372.4M | 404.7M | 377.4M | 284.3M | 292.3M | |
INVESTING ACTIVITIES | ||||||||
-129.6M | -118.1M | -108.9M | -89.7M | -84.6M | -70.8M | -66.4M | -63.6M | |
(0.0) | (0.0) | -140.9M | (0.0) | -149.4M | -140M | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | -15M | (0.0) | (0.0) | (0.0) | (0.0) | |
16M | 0.0 | 0.0 | 289K | 0.0 | 0.0 | 0.0 | 0.0 | |
-7.4M | 0.0 | 0.0 | 0.0 | 5.6M | 0.0 | 0.0 | 0.0 | |
-121M | -118.1M | -249.8M | -104.4M | -228.4M | -210.8M | -66.4M | -63.6M | |
FINANCING ACTIVITIES | ||||||||
1.7M | -10.4M | -14.7M | -100M | -103.8M | -101.1M | 0.0 | 0.0 | |
4.7M | -28.1M | -165.8M | -13.3M | -10.9M | 2.2B | -201.1M | -245.2M | |
(0.0) | -10.4M | -15.2M | -100M | -103.8M | -101.1M | (0.0) | (0.0) | |
-4.1M | -2.9M | -465K | -2.5M | 0.0 | -2.2B | 0.0 | 0.0 | |
2.4M | -41.3M | -181M | -115.7M | -114.7M | -61.6M | -201.1M | -245.2M | |
CASH FLOW SUMMARY | ||||||||
-1.3M | -51.8M | -259.1M | 152.2M | 61.6M | 104.9M | 16.8M | -16.4M | |
29.7M | 81.5M | 340.6M | 188.4M | 126.8M | 21.8M | 5M | 21.4M | |
28.3M | 29.7M | 81.5M | 340.6M | 188.4M | 126.8M | 21.8M | 5M | |
-12.3M | -10.5M | 62.9M | 282.6M | 320.1M | 306.6M | 217.9M | 228.7M |
CTEV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 20, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 15, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 29, 2025 | December 23, 2025 | 2025 |
Continue your CTEV research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.